Clinical and Translational Science Award

临床和转化科学奖

• 批准号: 9886296
• 负责人: MARLA J KELLER
• 金额: $ 427.42万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-03-22 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9886296
• 关键词: Advisory Committees; Aging; Appointment; Biological Assay; Biological Markers; Biomedical Research; Caring; Child Health; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Clinical and Translational Science Awards; Collaborations; Communities; Community Healthcare; Competence; Drug Design; Ecosystem; Evaluation; Faculty; Fostering; Funding; Gender; Generations; Goals; Health Care Research; Healthcare; Informatics; Infrastructure; Institutes; Integrated Health Care Systems; Investments; Knowledge; Laboratory Research; Leadership; Longevity; Mentors; Methods; Mission; Multi-Institutional Clinical Trial; New York City; Pathway interactions; Phase; Pilot Projects; Play; Positioning Attribute; Process; Research; Research Personnel; Research Support; Resource Development; Resources; Role; Safety; Scientist; Services; Structure; Training; Training and Education; Translational Research; Work; Workforce Development; authority; biobank; biomedical informatics; career development; clinical practice; implementation science; improved; innovation; named group; next generation; novel; novel diagnostics; novel therapeutics; patient safety; population health; practice-based research network; precision medicine; programs; translational pipeline

The Einstein-Montefiore Institute for Clinical and Translational Research (ICTR) has evolved over the past two CTSA funding periods, embracing the broad spectrum of clinical and translational (C/T) biomedical research from T1 through T4. We have provided pathways for our clinicians and our integrated healthcare system to expand implementation science, population health, community-engaged research, and clinical trials while also encouraging basic scientists to innovate new therapeutics and diagnostics. This broad involvement with our community and investigators has allowed the CTSA to impact a wide range of research extending from drug design and improving clinical trials management, to training a new research workforce, and to using implementation science for community-engaged and healthcare research. Indeed, the ICTR’s mission—to advance research across the translational spectrum into clinical practice through its integrated infrastructure, innovative training, and institutional co-investment—has evolved in step with that of the National Center for Advancing Translational Sciences. In this application, we will 1) leverage CTSA resources with institutional assets that support state-of-the-art informatics to accelerate the transfer of discoveries to healthcare via an Evidence Generation Framework, and support regulatory streamlining, innovative analytics, and assist with all phases of C/T research; 2) develop the next generation of research workforce and teams, using novel education, training, mentoring, pilot study support, and career development resources that span translational domains; 3) expand collaborations and engagement, both with the CTSA network and other hubs, and the Bronx community and healthcare partners in an integrative paradigm with strategies developed in collaboration with community partners, investigators, and institutional leadership to improve population health; 4) advance life span, child health, and aging research across genders and special populations, by working with unique platforms for stakeholder-engaged research, patient safety and implementation science, the Montefiore Accountable Care Organization, and the New York City Practice-Based Research Network; and 5) innovate methods and processes that advance C/T sciences, and enhance quality, safety, and efficiency of C/T research. We will integrate the CTSA Trial Innovation Network into our ecosystem of multisite clinical trials, foster innovative methods for biomarker assays and biobanking for precision medicine, and leverage the CTSA Common Metrics Initiative to support our hub’s Evaluation and strategic management. Overall, the Einstein- Montefiore ICTR will fulfill NCATS’s tripartite mission to innovate, educate, and implement.

爱因斯坦-蒙蒂菲奥里临床与转化研究所 (ICTR) 在过去两年中不断发展 CTSA 资助期限，涵盖广泛的临床和转化 (C/T) 生物医学研究 从 T1 到 T4，我们为我们的长者和我们的综合医疗保健系统提供了实现这一目标的途径。 扩大实施科学、人口健康、社区参与研究和临床试验，同时也 鼓励基础科学家创新新的治疗方法和诊断方法。 社区和研究人员使 CTSA 能够影响从药物延伸到广泛的研究 设计和改进临床试验管理，培训新的研究人员，并使用 事实上，卢旺达问题国际法庭的使命是促进社区参与和医疗保健研究的实施科学。 通过其综合基础设施，跨转化领域的研究进入临床实践， 创新培训和机构共同投资——与国家中心同步发展 推进转化科学 在本应用中，我们将 1) 利用机构的 CTSA 资源。 支持最先进信息学的资产，通过 证据生成框架，支持监管简化、创新分析，并协助所有 C/T 研究的各个阶段；2）利用新颖的方法培养下一代研究人员和团队 涵盖转化的教育、培训、指导、试点研究支持和职业发展资源 3) 扩大与 CTSA 网络和其他中心的合作和参与，以及 布朗克斯社区和医疗保健合作伙伴采用综合范式，并共同制定战略 与社区合作伙伴、研究人员和机构领导一起改善人口健康；4) 通过与独特的合作，跨性别和特殊人群的寿命、儿童健康和老龄化研究 利益相关者参与研究、患者安全和科学实施的平台，Montefiore 责任医疗组织和纽约市基于实践的研究网络以及 5) 创新； 推进 C/T 科学并提高 C/T 质量、安全性和效率的方法和流程 我们将把 CTSA 试验创新网络整合到我们的多中心临床试验生态系统中， 培育精准医学生物标志物检测和生物样本库的创新方法，并利用 CTSA 通用指标倡议支持我们中心的评估和战略管理总体而言，爱因斯坦- Montefiore ICTR 将履行 NCATS 的创新、教育和实施三方使命。